Picture Berlin Partner Hotspot for Startups 650x80px
Collaboration › Details

Fluidigm–Leucadia: investor conference, 201906 supply service Fluidigm presents at Jefferies Healthcare Conference in New York


Period Period 2019-06-04
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st Fluidigm Corporation (Nasdaq: FLDM)
  Group Fluidigm (Group)
  Partner, 2nd Jefferies LLC
  Group Leucadia (Group)
Products Product Jefferies 2019 Global Healthcare Conference New York
  Product 2 CyTOF® mass cytometer
Persons Person Jog, Vikram (Fluidigm 200802– CFO before XDx CFO + Applera)
  Person 2 Lee, Agnes (Fluidigm 201806 VP Investor Relations)

Fluidigm Corporation. (5/9/19). "Press Release: Fluidigm to Participate in Upcoming Health Care Investor Conferences". South San Francisco, CA.

Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences.

> Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York.

> Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York. A breakout will follow the presentation at 2:00 pm ET.

A live webcast of the company’s fireside chat, presentation and subsequent replay will be available in the Events & Presentations section of the Company’s investor website. The webcast will be available one hour after the conclusion of the events and will be archived for 90 days following the live presentation.

About Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit

Fluidigm and the Fluidigm logo are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.


Fluidigm Corporation

Agnes Lee
Vice President, Investor Relations
650 416 7423

Record changed: 2019-10-11


Picture [iito] No Tracking 650x80px

More documents for Fluidigm (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Global Partnering Four Events One Price 650x80

» top